Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 0/1 Topical Application of the Monoclonal Antibody (Mab) sB24M in Patients With Severe Pyoderma

NCT04895566 is registered in ClinicalTrials.gov with SWISS BIOPHARMA MED GmbH as lead sponsor.

NCT NCT04895566
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04895566 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 0/1 Topical Application of the Monoclonal Antibody (Mab) sB24M in Patients With Severe Pyoderma
Lead sponsor
SWISS BIOPHARMA MED GmbH
Phase
Phase 1
Overall status
Completed
Start date
May 24, 2021
Completion date
March 16, 2023
Enrollment
10 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

pyoderma, pyoderma gangrenosum, pyoderma gangrenosum surrounding surgical stoma, pyoderma vegetans